Current Size: 100%

News

Highly efficient protein production system introduced by researchers from LBI-CR

Recombinant protein production remains a central component of many biotechnological projects. As mammalian proteins frequently require extensive post-translational modification, mammalian cells are often used for recombinant protein production instead of yeast and bacteria. Intuitively, a protein will be best expressed in its native cell type under physiological conditions, where a multitude of
molecular systems work together for efficient production and quality control at various stages, including synthesis and folding, post-translational modifications and subcellular targeting. However, as mammalian cell culture is costly and establisment of efficiently producing cell lines can be a lengthy procedure, productivity is an important determinant.

LBI-CR participates in successful bid for European Training Network

The European Research Initiative of ALK-related malignancies (ERIA) forms the core of a successful proposal for a European Training  Network (ETN). Suzanne Turner of the University of Cambridge, Lukas Kenner (LBI-CR) and Olaf Merkel (Medical University Vienna) formed a consortium around some of the leading researchers focussing in malignancies driven by the oncogene ALK to facilitate the development of less-toxic and more efficacious therapies. The consortium developed a competitive training programme for twelve PhD students, which is complemented by an array of companies.

Jan Pencik receives "Young Investigator Award" of the prestigious Charles Rodolphe Brupbacher Foundation

Klaus W. Grätz (Decan of Medical Fakulty), Georg Umbricht (Stiftungsrat), Michael Kiessling, Hella A. Bolck, Jan Pencik, Phil F. Cheng, Christian M. Schürch, Markus G. Manz (Director Klinik für Hämatologie and Scientific Organisor)

The Charles Rodolphe Brupbacher Foundation bestowed recently their biennial prize to five young investigators, who contributed to their Scientific Symposium 2015. Jan Pencik received one of these awards for his research on "Aberrant STAT3-ARF signaling targets distinct subgroups of lethal prostate cancer".

New publication reports STAT5 regulates stem cell proliferation during regeneration in the gut

The human gut has the largest surface area (400 m2) among all organs, whose size and shape are actively controlled and maintained. The gastrointestinal tract poses severe clinical problems upon chronic injury as in inflammatory bowel disease (ulcerative colitis and Crohn´s disease) during chemotherapy or targeted therapy. At least seven unique differentiated cell types are known to form the gut and they originate from intestinal epithelial stem cells (IESC). Homeostasis refers to the process maintaining the size of an organ through controlling the overall number of cells.

First ERC starting grant for researcher at Ludwig Boltzmann Institute

Dr. Florian Grebien, shortlisted for a ERC starting grant

Florian Grebien of the Ludwig Boltzmann Institute for Cancer Research (LBI-CR) will receive a coveted Starting Grants of the European Research Council (ERC). It is the first ERC Grant, for a researcher at the Ludwig Boltzmann Gesellschaft. With the aid of EUR 1.5 million funding Grebien will expand its research group, which he founded in January 2014 with the support of the Institute. He explores how blood cancer develops and progresses with a specially developed technology platform.

LBI-CR participates in LBG-Health Sciences Meeting

The goal of the meeting is to promote and support scientists by offering them a stage to present their work and to give them a chance to assert themselves within the scientific setting, connect with other players of the health sciences community and to start new cooperations. Therefore every research area had its own session including a key note lecture and four oral presentations of the best submitted abstracts. The oral presentations in oncology were moderated by Prof. Richard Moriggl, who welcomed Prof. Nancy Hynes from the FMI in Basel to present her research on breast cancer.

Pages